Dermatologic diseases are complex. Getting valuable insights shouldn't be.

Improve R&D with Real-World Data and AI

OM1 is a leading technology-enabled health data company reimagining real-world data and evidence in specialized therapeutic areas.

OM1 develops large, electronically connected networks of clinicians in key specialty areas. This ebook explores powerful insights, analyses, and use cases from OM1’s Dermatology Network.

Meet the largest Dermatology Data Network in the U.S.

A comprehensive view of the patient journey from clinical development to the clinic

Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to support your programs shouldn’t be. That’s why OM1 and the American Academy of Dermatology joined forces in connecting the DataDerm™ Registry with the OM1 Real-World Data Cloud. Together, we’ve built the largest dermatology network in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.

Dermatology Real-World Data Network

*Counts are subject to change

OM1 Dermatology Network

A broadly representative, specialty-focused network designed for:

Retrospective studies
Prospective studies, including ClinRO and PRO
Data products for license
External control arm development
Clinical trial planning/recruitment
Post-market surveillance
Commercial intelligence

Incorporating AAD’s DataDerm^TM and site EMR data
Additional dermatology practices across the U.S. from OM1 Networks
All 50 US States

How We can Help

Clinical Development

Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as seeing where unmet needs are greatest or determining which groups the protocol should be designed to enroll.

Safety & Regulatory

Measure key safety outcomes of interest and support regulatory requirements such as monitoring and comparing the real-world safety profiles for patients on JAK Inhibitors.

Medical Affairs

Align with real world-based patient behaviors to measure adherence to novel treatment approaches such as for atopic dermatitis.

Market Access & HEOR

Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization. For example, assess the cost effectiveness of early treatment interventions for psoriatic arthritis.

Commercial

RWD can help guide planning, forecasting, and improving brand performance such as understanding the size of the market by segment in PsO patient subtypes that are best aligned with a brand’s positioning.